Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

Autor: Jo Wright, Shaun R. Seaman, Rob Howes, Giles Wright, Mark Ferris, Paul J. Lehner, Ashley Shaw, Natalie Quinnell, Lucy Rivett, Nick K Jones, Richard J. Samworth, Michael P. Weekes, Chris Workman, Nicholas J Matheson, Ian Goodfellow, Ben Warne
Přispěvatelé: Jones, Nick K [0000-0003-4475-7761], Rivett, Lucy [0000-0002-2781-9345], Goodfellow, Ian G [0000-0002-9483-510X], Lehner, Paul J [0000-0001-9383-1054], Matheson, Nicholas J [0000-0002-3318-1851], Weekes, Michael P [0000-0003-3196-5545], Apollo - University of Cambridge Repository
Rok vydání: 2021
Předmět:
0301 basic medicine
global health
Disease
0302 clinical medicine
Pandemic
Epidemiology
Global health
Medicine
Biology (General)
Asymptomatic Infections
Microbiology and Infectious Disease
Transmission (medicine)
General Neuroscience
Vaccination
General Medicine
3. Good health
epidemiology
medicine.symptom
Human
medicine.medical_specialty
COVID-19 Vaccines
QH301-705.5
Science
infectious disease
Health Personnel
Immunization
Secondary
Asymptomatic
General Biochemistry
Genetics and Molecular Biology
03 medical and health sciences
Internal medicine
Humans
asymptomatic
Infectious disease (athletes)
BNT162 Vaccine
Immunization Schedule
General Immunology and Microbiology
SARS-CoV-2
business.industry
microbiology
COVID-19
Epidemiology and Global Health
030104 developmental biology
BNT162b2
Pfizer-BioNTech
Research Advance
business
030217 neurology & neurosurgery
Zdroj: eLife
eLife, Vol 10 (2021)
ISSN: 2050-084X
DOI: 10.7554/elife.68808
Popis: The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of asymptomatic SARS-CoV-2 infection remains unknown. We previously demonstrated frequent pauci- and asymptomatic SARS-CoV-2 infection amongst healthcare workers (HCWs) during the UK’s first wave of the COVID-19 pandemic, using a comprehensive PCR-based HCW screening programme (Rivett et al., 2020; Jones et al., 2020). Here, we evaluate the effect of first-dose BNT162b2 vaccination on test positivity rates and find a fourfold reduction in asymptomatic infection amongst HCWs ≥12 days post-vaccination. These data provide real-world evidence of short-term protection against asymptomatic SARS-CoV-2 infection following a single dose of BNT162b2 vaccine, suggesting that mass first-dose vaccination will reduce SARS-CoV-2 transmission, as well as the burden of COVID-19 disease.
Databáze: OpenAIRE
Externí odkaz: